SCHEMBL613040

SCHEMBL613040

Oc1ccc(Cl)c(-c2ccc3nc(Nc4ccc(Oc5ccccc5)cc4)nn3c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.52
JAK2 O60674 2/20 0.48
TTK P33981 9/20 0.43
JAK3 P52333 1/20 0.39
PIK3CG P48736 3/20 0.38
PIK3CD O00329 2/20 0.38
SRC P12931 2/20 0.38
CIT O14578 1/20 0.38
GAK O14976 1/20 0.38
EPHB6 O15197 1/20 0.38
RIPK2 O43353 1/20 0.38
PRKD3 O94806 1/20 0.38
ABL1 P00519 1/20 0.38
LCK P06239 1/20 0.38
YES1 P07947 1/20 0.38
RET P07949 1/20 0.38
PDGFRB P09619 1/20 0.38
BCR P11274 1/20 0.38
BRAF P15056 1/20 0.38
EPHA2 P29317 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL615192 0.89 LRRK2 (0.48) LRRK2JAK2TTKSRCCIT
SCHEMBL613005 0.85 LRRK2 (0.44) LRRK2JAK2TTKSRCCIT
SCHEMBL612376 0.85 SRC (0.46) LRRK2JAK2TTKJAK3PIK3CG
SCHEMBL41292 0.83 LRRK2 (0.49) LRRK2JAK2TTKJAK3PIK3CG
SCHEMBL41597 0.83 LRRK2 (0.47) LRRK2JAK2TTKJAK3PIK3CG
SCHEMBL613379 0.83 LRRK2 (0.47) LRRK2JAK2TTKJAK3PIK3CG
SCHEMBL614357 0.82 SYK (0.43) LRRK2JAK2TTKPIK3CGPIK3CD
SCHEMBL613798 0.82 ESR1 (0.45) LRRK2JAK2TTKSRCCIT
SCHEMBL41122 0.81 SRC (0.53) LRRK2JAK2TTKPIK3CGSRC
SCHEMBL41482 0.81 LRRK2 (0.46) LRRK2JAK2TTKPIK3CGPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041195-A1 Heterocyclic compounds FOVEA PHARMACEUTICALS 2012-02-16 US claimed
EP-2396324-A1 Ý1, 2, 4¨TRIAZOLO Ý1, 5 -A¨PYRIDINES AS KINASE INHIBITORS Fovea Pharmaceuticals (FR) 2011-12-21 EP claimed
WO-2010092041-A1 [1, 2, 4] TRIAZOLO [1, 5 -A] PYRIDINES AS KINASE INHIBITORS FOVEA PHARMACEUTICALS SA (FR) 2010-08-19 WO claimed
US-20120041195-A1 Heterocyclic compounds FOVEA PHARMACEUTICALS 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041195-A1 Heterocyclic compounds MAP3K1, MAP3K5, MAP3K2 LRRK2 391/4885JAK2 325/4885TTK 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.